Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 05, 2020 16:10 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

Company continues to develop ALRN-6924 as novel chemoprotective medicine to protect patients from chemotherapy-induced toxicities and side effects-- Positive interim dose optimization data from...
August 03, 2020 08:10 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics to Present at Two Upcoming Investor Conferences in August

WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participate in two...
August 03, 2020 08:00 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Announces Completion of Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924

Study is evaluating ALRN-6924 to protect against chemotherapy-induced bone marrow toxicities in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecanPreviously reported...
May 30, 2019 08:00 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics to Present at the Jefferies 2019 Healthcare Conference

WATERTOWN, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other...
November 07, 2018 16:10 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Reports Third Quarter 2018 Financial Results

Manuel Aivado, MD, PhD, promoted to President and Chief Executive OfficerVojislav Vukovic, MD, appointed Senior Vice President, Chief Medical Officer, and Allen Annis, PhD, promoted to Senior Vice...
September 06, 2018 09:00 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer

WATERTOWN, Mass., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today...
August 07, 2018 16:15 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Reports Second Quarter 2018 Financial Results

Preclinical in-vivo ALRN-6924 combination data with CDK4/6 inhibitors, PD-1/-L1 inhibitors, or paclitaxel (formulated as Abraxane or Taxol) all show promise in breast cancer and other cancer models...
August 02, 2018 07:00 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics to Present at the Canaccord Genuity 38th Annual Growth Conference

CAMBRIDGE, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that...
July 31, 2018 07:00 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics to Report Second Quarter 2018 Financial Results on August 7, 2018

CAMBRIDGE, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that...
May 29, 2018 07:00 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

CAMBRIDGE, Mass., May 29, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that...